ArticleJournal of cosmetic dermatology2025
Comparison of Topical 20% Azelaic Acid and 7.5% Dapsone in the Treatment of Mild-To-Moderate Papulopustular Rosacea.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Latest Advances in Rosacea Treatment: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A Comprehensive Review of Azelaic Acid Pharmacological Properties, Clinical Applications, and Innovative Topical Formulations.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRosacea is a chronic inflammatory skin disease, commonly affecting the central part of the face, characterized by erythema, flushing, telangiectasias, papules, and pustules. It may also involve sensations of burning, tingling, and occasionally fibrous changes.
aimThis study aims to compare the efficacy, side effect profiles, and patient satisfaction of topical 20% azelaic acid and 7.5% dapsone in the treatment of mild-to-moderate papulopustular rosacea (Stage 2).
methodsEthics approval was obtained. A retrospective analysis was conducted on the medical records of 76 patients, including 44 in the azelaic acid group and 32 in the dapsone group, all diagnosed with mild-to-moderate papulopustular rosacea. These patients were treated with either topical azelaic acid or dapsone at the dermatology outpatient clinic between August 1, 2022 and December 31, 2022. Demographic characteristics, Investigator's Global Assessment scores, lesion counts, erythema scores, side effects, and patient satisfaction data were analyzed in the study.
resultsNo statistically significant differences were found between groups based on pretreatment IGA values, separate IGA scores (2-4), lesion counts, average erythema scores, or separate erythema scores (p > 0.05 for all). Within each group, comparisons of pre- and posttreatment IGA values, lesion counts, and erythema scores revealed statistically significant differences (p < 0.001 for all), indicating that both treatments were effective. When comparing the groups based on posttreatment IGA values, separate IGA scores (0-3), improvement percentages in IGA values, lesion counts, improvement percentages in lesion counts, average erythema scores, separate erythema scores (0-2), and improvement percentages in erythema scores, no significant differences were observed (p > 0.05 for all).
conclusionTopical dapsone is as effective as azelaic acid in treating mild-to-moderate papulopustular rosacea and is associated with fewer side effects, making it a safer option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.